[
  {
    "symbol": "VERA",
    "timestamp": "2024-12-22 11:31:12",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's\u00a0product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/dmVyYXR4LmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/dmVyYXR4LmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "price": 42.6,
    "priceChange": 1.3079667063020317,
    "openPrice": 41.66,
    "prevClose": 42.05,
    "dayHigh": 45.06,
    "dayLow": 40.96,
    "volume": 2044412.0,
    "prevVolume": 544642,
    "volumeMetrics": {
      "recentVolumes": [
        354682,
        536689,
        560756,
        544642,
        2044412.0
      ],
      "volumeDates": [
        "2024-12-15",
        "2024-12-16",
        "2024-12-17",
        "2024-12-18",
        "2024-12-19"
      ],
      "dailyChanges": [
        51.32,
        4.48,
        -2.87,
        275.37
      ],
      "averageVolume": 746586.375,
      "volumeChange": 275.37,
      "volumeVsAvg": 173.83
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 746586.375
    },
    "fiftyTwoWeekHigh": 51.61,
    "fiftyTwoWeekLow": 14.2,
    "highProximityPct": 17.457857004456496,
    "marketCap": 2697562057.8,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 0
      }
    },
    "recentNews": [
      {
        "title": "Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-12-09T23:29:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/12/09/2994136/0/en/Vera-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
        "type": "VERA"
      },
      {
        "title": "Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-28T21:37:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/28/2970400/0/en/Vera-Therapeutics-Announces-Proposed-Public-Offering-of-Class-A-Common-Stock.html",
        "type": "VERA"
      },
      {
        "title": "Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-26T23:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/26/2969705/0/en/Vera-Therapeutics-Announces-96-week-eGFR-Stabilization-in-ORIGIN-Phase-2b-Study-of-Atacicept-in-IgAN-in-a-Late-Breaking-Oral-Presentation-at-the-American-Society-of-Nephrology-Kidn.html",
        "type": "VERA"
      },
      {
        "title": "Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-07-05T20:31:33Z",
        "url": "https://www.globenewswire.com/news-release/2024/07/05/2909190/0/en/Vera-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
        "type": "VERA"
      },
      {
        "title": "Vera Therapeutics Appoints Christy J. Oliger to Board of Directors",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-11T20:01:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/11/2897152/0/en/Vera-Therapeutics-Appoints-Christy-J-Oliger-to-Board-of-Directors.html",
        "type": "VERA"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": null
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [
          0.0,
          0.0,
          0.0,
          0.0,
          NaN
        ],
        "revenueChanges": [
          null,
          null,
          null,
          null,
          null
        ],
        "netIncome": [
          -95990000.0,
          -89056000.0,
          -32609000.0,
          -53413000.0,
          NaN
        ],
        "netIncomeChanges": [
          null,
          null,
          null,
          null,
          null
        ],
        "operatingMargin": [
          0,
          0,
          0,
          0,
          NaN
        ],
        "operatingMarginChanges": [
          null,
          null,
          null,
          null,
          null
        ],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": [
          "2023-12-31",
          "2022-12-31",
          "2021-12-31",
          "2020-12-31",
          "2019-12-31"
        ]
      }
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  }
]